TP53 – Medxy AI

Molecular Stratification of Early-Stage Vulvar Squamous Cell Carcinoma: Prognostic Impact of HPV and TP53 Status

By MedXY 09/19/2026

This study highlights how HPV and TP53 molecular subtyping in stage I vulvar squamous cell carcinoma delineates survival outcomes and recurrence risks, supporting its role in personalized management strategies.

Hematology-Oncology news Oncology

Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX Models

By MedXY 05/27/2026

MD-265, a PROTAC MDM2 degrader, showed strong anti-leukemia activity in primary AML cells and mouse PDX models, outperformed a conventional MDM2 inhibitor, and spared normal stem cells relatively well.

Hematology-Oncology news Oncology

Beyond Complexity: Why Molecular Features Still Dictate the Prognosis of Chronic Lymphocytic Leukemia

By MedXY 03/13/2026

Emerging data from UK clinical trials indicate that while high genomic complexity (HGC) correlates with poor outcomes in CLL, it often serves as a surrogate for other established high-risk markers like TP53 status and telomere length.